Stocks
Trump’s announcement could directly affect CSL, but we expect the firm to respond accordingly.
Stocks
Notable contract win, but market is limited.
Stocks
The sell-off in this moated healthcare company ignores strong potential for revenue growth and margin improvement.
Stocks
Cochlear’s biggest market segment has matured and it is looking elsewhere for growth.
Stocks
We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.
Stocks
Niche play with more growth potential than many investors give it credit for.
Stocks
The market cheers update from the company.
Stocks
The company is poised to take advantage of clear overarching macro revenue drivers.
Stocks
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
of 5
Viewing 1 to 10 of 47